Photo: Shutterstock
The deal, if approved, would rank among the biggest mergers in the biopharma industry.
January 03, 2019 at 04:16 PM
1 minute read
The original version of this story was published on The American Lawyer
Kirkland & Ellis and Wachtell, Lipton, Rosen & Katz are advising on the proposed $74 billion acquisition by pharmaceutical giant Bristol-Myers Squibb of New Jersey-based biotechnology firm Celgene Corp.
The deal, which would unite the resources of two of the world’s pioneers in the treatment of cancer, cardiovascular disease and other maladies, is expected to close in the third quarter of 2019, subject to antitrust and regulatory approval.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
